



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY



Cairo University

Faculty of Veterinary Medicine

**Pathological, immunohistochemical and molecular studies on the
curative role of synthetic cannabinoid receptors-2 agonist (AM1241)
in induced hepatic and pulmonary fibrosis in male rats**

A thesis submitted by

Alaa Mohamed Ali

(BVSc, Cairo University, 2013; MVSc, Cairo University, 2017)

For the degree of the Ph.D.

(pathology)

(General, Special and Postmortem)

Under Supervision of

Prof. Dr. Sahar Samir Mahmoud Abd El-Rahman

Professor of pathology, Faculty of Veterinary Medicine, Cairo University.

Prof. Dr. Osama Samir Zaky El-Tawil

Professor of toxicology and forensic medicine, Faculty of Veterinary Medicine,
Cairo University.

2021



Cairo University
Faculty of Veterinary Medicine
Department of pathology



Supervision Sheet

Prof. Dr. Sahar Samir Mahmoud Abd El-Rahman

Professor of pathology, Faculty of Veterinary Medicine, Cairo University.

Prof. Dr. Osama Samir Zaky El-Tawil

Professor of toxicology and forensic medicine, Faculty of Veterinary Medicine,
Cairo University.

2021

Cairo University
Faculty of Veterinary Medicine
Pathology Department

Name: Alaa Mohamed Ali

Date of birth: 15-12-1990

Nationality: Egyptian

Degree: PhD (General, Special and Postmortem)

Under supervised of:

- **Prof. Dr. Sahar Samir Mahmoud Abd El-Rahman**

Professor of pathology, Faculty of Veterinary Medicine, Cairo University.

- **Prof. Dr. Osama Samir Zaky El-Tawil**

Professor of toxicology and forensic medicine, Faculty of Veterinary Medicine, Cairo University.

Thesis Title: Pathological, immunohistochemical and molecular studies on the curative role of synthetic cannabinoid receptors-2 agonist (AM1241) in induced hepatic and pulmonary fibrosis in male rats

Abstract

The activation of cannabinoid receptor 2 (CB2) plays a pleiotropic role in the innate immunity and is considered a crucial mediator in liver and lung disease. This study aimed to explore the role of activating CB2 using synthetic agonist (AM1241) on suppressing the progress of liver fibrosis induced by two models; bile duct ligation (BDL) and TAA administration as well as lung fibrosis induced by bleomycin (BLM) instillation. The study also attempted to clarify the mechanisms of the antifibrotic effects of synthetic CB2 agonists; AM1241 on the ongoing both hepatic and pulmonary fibrosis. AM1241 was administrated to rats of the aforementioned three models in two doses (3 and 6 mg/kg) for 14 days (in BDL experiment) and 21days (for the other experiments). Liver function and oxidative stress markers, hepatic TNF- α , IL-6 and IL-10, IL-1 β , TGF- β 1, RT-qPCR expression of Toll like receptor 4 (TLR4), TGF- β 1, α -SMA and microRNA-155 (miR-155) genes, western blot for Vimentin and E-cadherin proteins, immunohistochemical expression of CD31, CD34, α -SMA and NF- κ B as well as histopathology of liver tissue were all assessed. In lung experiment, miRNA-21, Myd88 and TLR4 genes expression were detected by RT-q-PCR, while collagen I, Smad2 and Myd88 protein levels were analyzed by western blot. In addition, antioxidant activity (SOD and GSH), pro-fibrotic (TGF- β 1) and pro-inflammatory (IL-4 and IL-13) cytokines were determined in lung tissue homogenate using ELISA kits. Histological examination and immunohistochemical (IHC) evaluation of CD4, α -SMA and TGF- β 1 expression were also examined. In both liver models; AM1241 administration at both doses significantly ($P < 0.05$) ameliorated liver function markers, pro-inflammatory cytokines (TNF- α , IL-6), significantly decreased i GSH content and TLR4 gene expression. Histologically, AM1241 limited fibroplasia extension decreased immune-expression of NF- κ B in both models. While in BDL model, AM1241 showed significant increase in the immune-medulatory cytokine; IL-10, decreased immune-expression of CD31 and strongly expressed CD34. Regarding TAA induced liver fibrosis; AM1241 showed significant decrease in Vimentin level, TGF- β 1, α -SMA and microRNA-155 gene expression with significant increase in E-cadherin level. While in the lung model; AM1241 group resulted in significant decrease in western blot protein levels (TLR4,

Myd88 and miR-21) as well as cytokines level with significant upgrade the anti-oxidant activity. Lung fibrosis in AM1241 administrated rats was minimal rather than BLM group as confirmed by the Ashcroft scale of fibrosis. Moreover, AM1241 groups showed significant negative immunohisto-expression of CD4, α -SMA and TGF- β 1 in dissimilarity with BLM rats. In conclusion, this study points out that; CB2 receptors activation could curb both hepatic and pulmonary fibrosis via distinct mechanisms. The hepatic fibrosis in BDL model was suppressed through inhibition of TLR-4/NF- κ B pathway, while in TAA model it was terminated through inhibition of TLR4/miR-155/ NF κ B p65 pathway. In BLM models the pulmonary fibrosis was abolished via inhibiting TLR4/Myd88/miR-21/ TGF- β 1/Smad2 signaling pathway. Also, these results suggest that CB2 agonists display potent hepatoregenerative properties, in addition to their antifibrogenic effects.

Key words:

Cannabinoid receptor 2; AM1241; TLR4; Liver fibrosis; lung fibrosis; miR-21; miR-155; Myd88

Dedication

*My deep thanks to
my Mother,
my Father,
my lovely husband,
my sisters, brothers
and
my close friends*

*for their great cooperation and continuous
support*

during the whole work

Acknowledgment

*All thanks to our merciful **ALLAH** who gave me all the graces I enjoy in my life. His magnificent help and compassion gave me the ability and patience to finish this work.*

*I would like to direct my sincere gratitude to **Prof. Dr. Sahar Samir mahmoud** Professor of pathology, Faculty of Veterinary Medicine, Cairo University, for her precious supervision, infinite support, and endless encouragement during every single step that allowed me to finish my work smoothly, successfully and effectively.*

*I would like to express great thanks, deep gratitude and respect to my supervisor **Prof. Dr. Osama Samir Zaky**, Professor of toxicology and forensic medicine, Faculty of Veterinary Medicine, Cairo University., Faculty of Veterinary Medicine, Cairo University, for his valuable advice, follow up, and continuous care.*

It is of great pleasure for me to express my thanks and gratitude to all members of Department of Pathology , for their continuous help and support

LIST OF CONTENTS

Chapter (1): Introduction.....	1
<u>Chapter (2): Review of literature.....</u>	4
<u>Chapter (3): Published paper.....</u>	24
<u>Chapter (4): Discussion</u>	97
<u>Chapter (5): Conclusion and Recommendation.....</u>	115
<u>Chapter (6): English Summary</u>	116
<u>Chapter (7): References.....</u>	119
الملخص العربى	

List of tables

Table number	Titles	Page number
First published Paper		
Table 1	The oligonucleotide sequences of forward and reverse primers	28
Table 2	Effect of CB ₂ -activation (AM1241) on serum biochemical markers in bile duct ligation model	28
Table 3	The relative gene expression of TLR4 in sham group and other treated groups	28
Table 4	Correspondence between area of fibrosis intensity, as assessed by image analysis in whole sections and the Metavir scoring	28
Second paper under publication		
Table 1	The oligonucleotide sequences of forward and reverse primers	41
Table 2	Primary antibodies and dilutions used for Western Blot analyses	42
Table 3	Effect of CB ₂ -activation (AM1241) on serum biochemical markers in different groups	44
Table 4	The relative gene expression of TLR4, TGF- β 1, α -SMA and miR-155 in control group and other treated groups	46
Third submitted paper		
Table 1	The oligonucleotide sequences of forward and reverse primers for TLR4, miR-21 and Myd88 genes	71
Table 2	The relative gene expression of TLR4, Myd88 and miR-21 in control group and other treated groups	75

List of figures

Figure number	Titles	Page number
First published Paper		
Figure 1	Effect of CB2- activator AM1241 on hepatic tissue homogenate of oxidative stress markers, TNF- α , IL-6 and IL-10 in bile duct ligation model. N=9; Values are expressed as mean \pm SE. Data were analyzed by using one way ANOVA followed by Tukey post-hoc test, a, b, c, d and e are significant at P < 0.05	27
Figure 2	H&E stained sections; AM1241 interfered the progress of hepatic fibrosis associated with bile duct ligation (BDL). (a) Liver of control rat showing normal histological structure. (b-e). Liver of BDL rat showing; (b) marked proliferation of the bile duct epithelium with many newly formed bile ducteols (dashed arrows) and mononuclear inflammatory cells infiltration (arrow), (c) insinuation of the proliferated cholangiocytes among the parenchymal cells accompanying proliferated oval cells (arrow), (d) many apoptotic bodies and cells (arrow), (e) fibroplasia (F) with marked pseudolobulation (PL) of the hepatic parenchyma. (f and g) Liver of BDL rat that treated with Silymarin showing mild portal fibroplasia, moderate cholangiocytes' proliferation and multiple newly formed bile ducteols (arrow). (h) Liver of BDL rat that treated AM1241 (3mg/kg bwt) showing marked decreased cholangiolar epithelial proliferation and few portal inflammatory cells infiltration.	29
Figure 3	a and b; H&E stained liver sections of BDL rats that treated AM1241 (3 and 6mg/kg b wt, respectively) showing; (a) very mild portal fibroplasia without any evidence of peripheral extension, (b) explicit hepatic lobular regularity preservation. (c) Metavir scoring for fibrosis extension in control, BDL and different treated groups. (d- h) Masson's Trichrome stained liver sections; (d and e) BDL rat showing accretion in hepatic fibrous components in portal triads and peripherally, (f) silymarin administration to BDL rats reduced fibrous tissue proliferation, (g and h) AM1241 administration to BDL rats significantly decreased fibrous tissue proliferation. (i) The intensity of fibrous proliferation in different groups evaluated by image analysis software (Image J, 1.46a, NIH, USA)	29
Figure 4	Immunohistochemical analysis of α -SMA, (a) control rat showing normal positive α -SMA expression around portal vein, (b and c) BDL rat showing increased expression of α -SMA in the portal areas and along the fibrous tissue	30

	proliferation, (d) decreased expression of α -SMA in silymarin treated rat. (e and f) marked limitation of α -SMA expression in AM1241 (3 and 6mg/kg b wt,) administrated rats. (g) Quantitative image analysis of α -SMA positive brown color in 5 microscopic fields (the area for each microscopic field is 18.8913Sqmm). Values are expressed as mean \pm SE. Data were analyzed by using one way ANOVA followed by Tukey post-hoc test, a, b, c, d and e are significant at $P < 0.05$	
Figure 5	Immunohistochemical analysis of CD31, (a) control rat showing negative immune-expression of CD31, (b) BDL rat showing increased CD31 immune-reactive cells among the sinusoidal endothelial linings (c) decreased expression of CD31 in silymarin treated rat. (d and e) marked decreased expression of CD31 in AM1241 (3 and 6mg/kg b wt,) administrated rats. (f) Quantitative image analysis of CD31 expression in 5 microscopic fields (the area for each microscopic field is 18.8913Sqmm). Values are expressed as mean \pm SE. Data were analyzed by using one way ANOVA followed by Tukey post-hoc test, a, b, c, d and e are significant at $P < 0.05$.	30
Figure 6	Immunohistochemical analysis of NF- κ B, (a) control rat showing negative immune-expression of NF- κ B, (b and c) BDL rat showing increased NF- κ B among the hepatic parenchymal cells, (d) decreased expression of NF- κ B in silymarin treated rat. (e and f) significant decreased expression of NF- κ B in AM1241 (3 and 6mg/kg b wt,) administrated rats. (g) Quantitative image analysis of NF- κ B expression in 5 microscopic fields (the area for each microscopic field is 18.8913Sqmm). Values are expressed as mean \pm SE. Data were analyzed by using one way ANOVA followed by Tukey post-hoc test, a, b, c, d and e are significant at $P < 0.05$	31
Figure 7	Immunohistochemical analysis of CD34, (a) control rat showing negative immune-expression of CD34, (b) BDL rat showing mild immunopositivity of CD34, (c) increased immune expression of CD34 in silymarin treated rat. (d and e) marked dose related increased CD34 immune-positive cells in AM1241 (3 and 6mg/kg b wt,) administrated rats. (f) Quantitative image analysis of CD34 expression in 5 microscopic fields (the area for each microscopic field is 18.8913Sqmm). Values are expressed as mean \pm SE. Data were analyzed by using one way ANOVA followed by Tukey post-hoc test, a, b, c, d and e are significant at $P < 0.05$	31

Second Accepted paper		
Figure 1	<p>Effect of AM1241 on of oxidative stress markers, TNF-α and IL-6 in hepatic tissue homogenate of TAA-induced fibrosis rats' model.</p> <p>model N=11; Values are expressed as mean \pm SE. Data were analyzed by using one way ANOVA. *, #, \$ and ¥ were Significant differences at $P < 0.05$ as, * significantly difference when compared to control group, # when compared toTAA group, \$ when compared to silymarin, ¥ when compared to AM1241 3mg/Kg.</p>	45
Figure 2	<p>A) Levels of Vimentin and E-Cadherin measured by western blot technique in different groups. (B) Western blot protein band diagram.</p> <p>N=11; Values are expressed as mean \pm SE. Data were analyzed by using one way ANOVA. *, #, \$ and ¥ were Significant differences at $P < 0.05$ as, * significantly difference when compared to control group, # when compared toTAA group, \$ when compared to silymarin, ¥ when compared to AM1241 3mg/Kg</p>	47
Figure 3	<p>H&E stained photomicrographs of liver, (A) Control group, showing normal hepatic parenchyma, (B) TAA group, showing pseudo-lobulation with presence of complete fibrous septa connecting the portal areas (green arrows), note the presence of numerous apoptotic bodies at the periportal area (black arrows), (C) Silymarin group, showing vacuolation of hepatocytes with presence of incomplete septa emerging from the portal area and mild portal mononuclear cells infiltration, (D) AM1241(3mg/kg) group, showing mild hepatocellular degeneration and (E) AM1241(6mg/kg) group, showing apparently normal hepatic parenchyma.</p>	49
Figure 4	<p>Modified Ishak staging for hepatic activity index (HAI) for scoring of necro-inflammatory activity and staging of liver disease. (A) Ishak necro-inflammatory activity score, control group scored (0), data are presented as median using Kruskel-Wallis test followed the Mann-Whitney <i>U</i> test. Significantly different was considered at $P < 0.05$. (B) Ishak staging for liver fibrosis, data are presented as median (max-min) using Kruskel-Wallis test followed by the Mann-Whitney <i>U</i> test. Significantly different was considered at $P < 0.05$. N=11; Values are expressed as mean \pm SE. Data were analyzed by using one way ANOVA. *, #, \$ and ¥ were Significant differences at $P < 0.05$ as, * significantly difference when compared to control group, # when compared toTAA group, \$ when compared to silymarin, ¥ when compared to AM1241 3mg/Kg.</p>	50

Figure 5	Photomicrographs of liver (MTC) stained, (A) Control group, normal limited amount of fibrous tissue at the portal area, (B) TAA group, extensive portal fibroplasia with bridging fibrosis represented by numerous fibrous tissue septa connecting portal areas, (C) Silymarin group, showing mild portal fibroplasia with thin incomplete septa extending, (D) AM1241(3mg/kg) group and (E) AM1241(6mg/kg) group, showing limited portal fibroplasia, and (F) Fibrosis expressed as area percent, Values are expressed as mean \pm SE. Data were analyzed by using one way ANOVA followed by Tukey post-hoc test. *, #, \$ and ¥ were Significant differences at $P < 0.05$ as, * significantly difference when compared to control group, # when compared to TAA group, \$ when compared to silymarin and ¥ when compared to AM1241 3mg/Kg.	52
Figure 6	Photomicrographs of liver, expression of NF- κ B p65, Immune-stained, (A) Negative expression, (B) Intense diffuse expression, (C) Moderate expression, (D) and (E) Mild expression, (F) NF- κ B p65 expressed as area percent. Values are expressed as mean \pm SE. Data were analyzed by using one way ANOVA followed by Tukey post-hoc test. *, #, \$ and ¥ were Significant differences at $P < 0.05$ as, * significantly difference when compared to control group, # when compared to TAA group, \$ when compared to silymarin and ¥ when compared to AM1241 3mg/Kg.	53
Third submitted paper		
Figure 1	Effect of AM1241 on oxidative stress markers, IL-4, IL-13 and TGF- β 1 in lung tissue homogenate of BLM-induced fibrosis rats' model. N=11; Values are expressed as mean \pm SE. Data were analyzed by using one way ANOVA. *, # and \$ were Significant differences at $P < 0.05$, where; * significantly different when compared to control group, # significantly different when compared to BLM group, \$ significantly different when compared to AM1241 (3mg/kg).	74
Figure 2	Levels of Collagen I (A), Smad2 (B), and Myd88 (C) measured by western blot technique in various experimental groups. (D) Diagram of western blot protein bands. Values are expressed as mean \pm SE. Data were analyzed by using one way ANOVA. *, # and \$ were significant differences at $P < 0.05$, where; * significantly different when compared to control group, # when compared to BLM group, \$ when compared to AM3mg/Kg	76
Figure 3	H&E (A-L) and MTC (M-P) stained lung sections. (A) Control rat, showing the normal histological limits of lung tissue, (B-F) BLM instilled rat showing , (B) extensive thickening of the interstitial tissue (arrow) with fibrous tissue and(C)	78